It is an attractive therapeutic target in AML, as high CD123 expression on blasts confers poor outcomes and high CD123 expression is also enriched in primary induction failure/early-relapse AML [68,69,70]. This evidence concerns the gene IL3RA and acute myeloid leukemia.